Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.

What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?

We dig into:

• Lilly's decision to stop disclosing its Phase 1 pipeline
• The Camurus fluid crystal technology deal and what it means for long-acting GLP-1s
• Eloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicine
• How eloralintide compares to Novo Nordisk's cagrilintide
• Why the future of obesity treatment is a toolbox, not a scoreboard
• The access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gaps
• Retatrutide, quintuple agonists, and what's coming out of ADA 2026

If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.

🔔 Subscribe for weekly updates on obesity medicine, GLP-1 news, and what it all means for patients.

💊 Sponsored by Shed — visit TryShed.com and use code OTP25 to save 25% on obesity care.